Promising new data for Lilly's Alimta. | Pharma Marketletter | Find ...
Results from a Phase III study, published in the Journal of Clinical Oncology, demonstrate that Eli Lilly's Alimta (pemetrexed), in combination with cisplatin, is associated with superior survival duration compared with cisplatin alone in the treatment of patients with malignancy pleural mesothelioma, a locally-invasive and rapidly-fatal condition linked to asbestos exposure.


